Cost-effectiveness of Skin Cancer Referral and Consultation Using Teledermoscopy in Australia by Snoswell, Centaine L. et al.
1 
 
1. Title Page 
 
The cost-effectiveness of skin cancer referral and consultation using teledermoscopy in 
Australia 
 
Authors:  
Mrs Centaine L. Snoswell BPharm MPH 
School of Pharmacy, The University of Queensland, Brisbane, Australia 
 
Dr Liam J. Caffery BInfoTech DipAppScience(Diag Rad) PhD 
Centre for Online Health, The University of Queensland, Brisbane, Australia 
 
Prof Jennifer A. Whitty BPharm PhD 
School of Pharmacy, The University of Queensland, Brisbane, Australia 
Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, UK  
 
Prof H. Peter Soyer MD FACD 
Dermatology Research Centre, The University of Queensland, The University of Queensland 
Diamantina Institute, Translational Research Institute, Brisbane, Australia 
Dermatology Department, Princess Alexandra Hospital, Brisbane, Australia 
 
A/Prof Louisa G. Gordon PhD 
QIMR Berghofer Medical Research Institute, Brisbane, Australia 
School of Nursing, Queensland University of Technology, Brisbane, Australia 
School of Public Health, The University of Queensland, Brisbane, Australia 
 
Corresponding Author: 
Mrs Centaine Snoswell BPharm MPH (on behalf of all authors) 
Postal Address: Pharmacy Australia Centre of Excellence, 20 Cornwall Street, 
Woolloongabba, QLD, 4102, AUSTRALIA 
Email: centaine.snoswell@uqconnect.edu.au  
Disclosure Statement: Nil disclosures 
 
Word count (text): 2526 
Number of Figures: 3 
Number of Tables: 2  
2 
 
Key Points 
Question: Is teledermoscopy cost-effective for skin cancer referral and triage in Australia?  
 
Findings: Store-and-forward teledermoscopy skin cancer referral was estimated to cost 
AU$54.64 per person more than usual care, but enabled clinical resolution to be achieved 26 
days earlier. The incremental cost per day saved to clinical resolution was AU$2.10.  
 
Meaning: Incorporating teledermoscopy as a referral method for skin cancer in Australia has 
the potential to benefit patients by providing earlier clinical resolution at additional cost to 
Medicare. 
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2. Abstract 
Importance: International literature has shown that teledermoscopy referral may be a viable 
method for skin cancer referral, however no economic investigations have occurred in 
Australia.   
Objective: To assess the cost-effectiveness of teledermoscopy as a referral mechanism for 
skin cancer diagnosis and management in Australia. 
Design: Cost-effectiveness analysis using a decision-analytic model. 
Setting: Primary care 
Participants: Australian general population (modelled) 
Intervention: We compared the costs of teledermoscopy referral (electronic referral 
containing digital dermoscopic images) versus usual care (a written referral letter) for 
specialist dermatologist review of a suspected skin cancer. 
Main outcome measures: Cost and time in ‘days to clinical resolution’, where clinical 
resolution was defined as diagnosis by a dermatologist or excision by a general practitioner. 
Probabilistic sensitivity analysis was performed to examine the uncertainty of the main 
results.  
Results: Time to clinical resolution was 26 days earlier with teledermoscopy referral 
compared with usual care alone (95%Credible interval (CrI) 13 to 38). The estimated mean 
cost difference between teledermoscopy referral ($318.39) versus usual care ($263.75) was 
$54.64 (95%CrI $22.69 to $97.35) per person. The incremental cost per day saved to clinical 
resolution was $2.10 (95%CrI $0.87 to $5.29).  
Conclusion and Relevance: Using teledermoscopy for skin cancer referral and triage in 
Australia will cost $54.64 extra per case on average, but will result in clinical resolution 26 
days sooner than usual care. Implementation recommendations depend on the preferences of 
the Australian health system decision makers for either lower cost or expedited clinical 
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resolution. Further research around the clinical significance of expedited clinical resolution 
and its importance for patients could inform implementation recommendations for the 
Australian setting.  
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3. Text 
Introduction 
Skin cancer presents a global health challenge. In Australia, melanoma accounts for over 
10% of all diagnosed and reported cancers, with an estimated 13,280 new cases diagnosed in 
20161.  The incidence of melanoma is increasing. Keratinocyte skin cancers (squamous and 
basal cell carcinomas) and other skin cancers, are not nationally reported and occur between 
10 and 20 times more often than melanoma 1.  
 
Teledermatology is the provision of the dermatologic care at a distance using information and 
communication technology. Teledermatology often uses store-and-forward communication, 
where digital images of a skin lesion are captured, typically in primary care, and subsequently 
forwarded to a dermatologist along with clinical information for review or management 
advice. In addition to the provision of virtual consultations, teledermatology can also be used 
to facilitate the triage of referrals for specialist care. 2-5.  When compared to a written referral 
for specialist care, the visual information included in a teledermatology referral provides 
extra information to assist with appropriate triage and patient management. Teledermatology 
referrals can result in earlier assessment and treatment6, and reduced waiting times and 
waiting lists7. When clinically indicated, some patients do not need to be seen by a 
dermatologist and instead can be managed by their general practitioners (GPs) often under 
advice from a dermatologist8-10.  
 
Dermoscopy is a non-invasive diagnostic technique that links clinical dermatology and 
dermatopathology of pigmented and non-pigmented skin lesions by enabling the visualisation 
of morphological features not seen by the naked eye 11.  Teledermoscopy is a form of 
teledermatology that specifically involves the store-and-forwarding of digital dermoscopic 
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images. When compared to other imaging techniques, teledermoscopy improves diagnostic 
accuracy12,13.  Teledermoscopy is not currently reimbursed under Medicare (Australia’s 
universal health scheme funded by the federal government). 
 
At present there are no published economic evaluations for teledermoscopy services specific 
to the Australian healthcare system, and there are few international studies available14. The 
implementation of new models of care requires information on their comparative cost-
effectiveness. Therefore, the purpose of this study was to examine the cost-effectiveness of 
teledermoscopy as a referral mechanism for skin cancer diagnosis in Australia and determine 
its value for improving the management of skin cancer. 
 
Methods 
Overview 
The cost-effectiveness of teledermoscopy referral for a suspected skin cancer was compared 
to usual care using a decision-analytic model.  A teledermoscopy referral is an electronic 
referral to dermatologist containing digital dermoscopic images and clinical information. 
Whereas, usual care is a written referral from a GP containing clinical information only.  An 
ethics waiver was granted by The University of Queensland Human Ethics Research Office. 
 
The decision-analytic model was developed in TreeAge Pro© software (Release 2.1, 2016). 
The model represented pathways of clinical management of suspected skin cancer in a 
general adult population.  The model has two arms, one representing usual care for suspected 
skin cancer in Australia and one representing the teledermoscopy referral intervention ( 
Figure 1Figure 1). 
 
The end point was ‘clinical resolution’ defined as diagnosis by a dermatologist or excision of 
7 
 
lesion by a GP. Diagnostic outcomes were melanoma, keratinocyte skin cancer (squamous 
cell carcinoma or basal cell carcinoma), and benign neoplasms (clinically and 
dermoscopically mimicking melanoma or a keratinocyte skin cancer). Costs were estimated 
from the perspective of the Australian Commonwealth Government (administrators of the 
Medical Benefits Scheme, MBS), and included the costs of consultation, excision, and 
histopathology. Histopathology confirmation of excised lesions is required before claiming 
items on the MBS to ensure correct itemisation and payment for healthcare providers15.  
 
Comparative treatments 
In Australia, usual care for a patient begins with a visit to a GP. Suspicious skin lesions may 
be detected during routine skin checks or opportunistically when patients visit their GP for a 
different purpose. After examining the area of concern and performing a full skin check, the 
GP can perform a biopsy or excision for histopathology, or refer the patient to a 
dermatologist for management. If referral is selected; the GP will write a referral letter and 
forward it to a nominated dermatologist, or to the patient who can submit to a dermatologist 
of their choice. When the patient has a consultation with the dermatologist, the dermatologist 
will undertake a full skin examination with or without a dermoscope, take dermoscopic 
images where appropriate, and if necessary perform a biopsy or excision. This process may 
occur across single or multiple visits with either the GP and/or dermatologist.  
 
For teledermoscopy referral, rather than writing referrals, the GP captures and sends a 
teledermoscopy image with clinical notes to any participating dermatologist. Once reviewed 
by a dermatologist, the teledermoscopy information could either be used to advise the GP of 
management options (e.g. to excise or monitor), or if necessary, schedule the patient for an 
in-person dermatologist consultation.   
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Model inputs 
Data estimates that informed the model were sourced systematically from literature searches 
and government databases. Probability data were sourced from international publications that 
had performed studies with similar usual care and teledermoscopy referral intervention 
(Table 1). The Australian Bettering the Evaluation and Care of Health (BEACH) report 
informed treatment estimates for proportion of occasions when GPs chose monitoring (no 
active treatment) for suspicious lesions, or rate of referral to a dermatologist (Table 1)16. The 
BEACH program runs out of the University of Sydney and collects data about the clinical 
activities of Australian GPs.  
 
Cost data to inform the model were sourced from the Australian Department of Health MBS 
(Table 1). The dermatologist teledermoscopy consult fee was set to be the same as the 
dermatologist in-person consultation fee, $72.75, aligning with the Medicines Advisory 
Committee Applications for asynchronous store-and-forward reimbursement 17. Costs for 
excision of melanoma, keratinocyte skin cancer, and benign neoplasm were informed by 
relevant MBS item codes (Table 1)18. Since there are multiple MBS item codes for each type 
of skin lesion, a single price per lesion type was calculated using a weighted average.  
Average weighted costs were calculated using MBS data from March 2013 to April 2014, 
this timeframe was selected to align with the BEACH report 15,16.  
 
The measure of benefit for this analysis was ‘days to clinical resolution’. Clinical resolution 
was diagnosis by a dermatologist, or excision and histopathology by a GP. The time in days 
between a GP consultation and excision of a suspected skin cancer was set to one day, and is 
the same in both arms of the model. All other time information was taken from a prospective 
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cohort study performed in New Zealand with 300 participants in 20128. This study was 
selected because of the comparability of the New Zealand health system and skin cancer risk 
to Australia, alternatives were cohort studies from Spain or the Unitised States4,19.  
 
Analyses 
The model performed an expected values analysis by aggregating the probabilities and costs 
in the pathways to calculate the mean cost per person. The incremental cost-effectiveness 
ratio was calculated by dividing the difference in costs of the two options by the difference in 
days to clinical resolution (benefit). Cost inputs were in 2016 Australian dollars (AUD$).  
 
One-way sensitivity analysis was performed by separately varying all model inputs within 
plausible ranges of high and low values (from relevant sources or imputed, outlined Table 
1Table 1). Alternative probabilities were extracted from the published studies (Table 1Table 
1). Frequencies of doctors’ visits and pathology testing varied between one and three 
visits/tests which in turn affected service costs (Table 1Table 1).  
 
Probabilistic sensitivity analysis was undertaken by re-sampling the cost and probabilities 
(concurrently) within pre-specified distributions (Table 1Table 1). Cost estimates and 
probabilities were randomly re-sampled according to gamma and beta distributions, 
respectively (Table 1Table 1). One thousand Monte Carlo simulations were run resulting in a 
range of plausible costs and effects. This simulation data allowed for the estimation of 95% 
credible interval (CrI) for model results to address the uncertainty in the model inputs.  Each 
CrI was estimated by rank ordering the results sequentially and excluding the highest 2.5% 
and lowest 2.5% of values.  
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Results 
Teledermoscopy referral had a mean cost of $318.39 per case and took nine days to clinical 
resolution, while the usual care cost $263.75 with 35 days to clinical resolution (Table 3Table 
2). Therefore, teledermoscopy referral cost $54.64 (95%CrI $22.69 to $97.35) more per case 
than usual care alone, and was associated with a reduced time to clinical resolution by 26 
(95%CrI 14 to 38) days. This resulted in an incremental cost-effectiveness ratio of $2.10 
(95%CrI $0.87 to $5.29) per day saved to clinical resolution (Table 3Table 2). 
 
In one-way sensitivity analyses, the most influential cost components were pathology testing 
(minimum of one test, maximum of two), GP consultation fee (minimum of one appointment, 
maximum of three), teledermoscopy dermatologist consultation fee (minimum 50%, 
maximum 150%) (Figure 2Figure 2). Influential probability components were the probability 
of a GP referring their patients via teledermoscopy, and the probability that after a 
teledermoscopy consultation the dermatologist would instruct the patient to return to their 
referring practitioner for diagnosis or treatment.  As the number referred back to their GP 
decreased from 90% to 10% the incremental cost-effectiveness ratio changed from $1.55 to 
$6.23 per day to clinical resolution. This was to be expected as the cost-effectiveness of 
teledermoscopy after implementation would depend on the uptake of referrals using 
teledermoscopy by GPs and the number of in-person dermatologist appointments avoided. 
Results from the probabilistic sensitivity analyses showed costs ranging from $22.69-$97.35 
per person, and for time to clinical resolution was 13-38 days. This variation in estimates 
meant the overall incremental cost-effectiveness ratio was estimated between $0.87-$5.29 per 
day saved to resolution, as shown in Table 3Table 2. Figure 3Figure 3 shows a clear 
separation between the cost-effectiveness ratio of teledermoscopy and usual care; 
teledermoscopy had a higher cost with faster clinical resolution than usual care within the 
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modelled conditions.  
 
Discussion 
Teledermoscopy referral has the potential to increase the efficiency of a dermoscopic case of 
care, reduce unnecessary biopsies and reduce inappropriate referral for specialist 
consultations. This is the first study to evaluate the economic impact of teledermoscopy 
referral for the management of suspected skin cancers in the Australian context.  Under the 
modelled conditions, it was found that teledermoscopy referral would on average cost an 
additional $54.64 per case compared to usual care but would reduce time to clinical 
resolution by 26 days. Although using teledermoscopy referral can increase the overall cost 
of treatment, the extra $54.64 per case may be a justifiable cost for the Australia government 
for expedited diagnosis and treatment. 
 
Consistent with our findings, studies in other countries have demonstrated teledermoscopy 
services were of comparable or higher cost to usual care with positive benefits10,14,20,21. 
Internationally, teledermoscopy referral systems have been successfully piloted with similar 
benefits to those demonstrated by this model 8-10. These studies showed that when used as a 
referral method, teledermoscopy meant that 39-88% of patients did not have to attend an in-
person consultation with their dermatologist and were able to be managed by their GP14. Each 
patient referred to a dermatologist for a teledermoscopy consultation that resulted in GP 
management (rather than requiring an in-person dermatologist consultation) increased the 
cost-effectiveness of teledermoscopy referral because dermatologists attract a higher 
attendance fee than GPs (Figure 2Figure 2). In addition, accurate dermatologist diagnosis via 
teledermoscopy has the potential to avoid erroneously excising benign neoplasms, preventing 
excision and histopathology costs.  Teledermoscopy referral can optimise triage for in-person 
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dermatologist appointments, due to the visual information about the condition10,20,21. Thereby, 
ensuring dermatologist appointments are available for urgent cases when required14. 
 
The Australasian College of Dermatologist’s application to the Commonwealth’s Department 
of Health to fund teledermoscopy under Medicare proposed an equal reimbursement for 
store-and-forward teledermatology compared with in-person care17.  Reducing the 
consultation fee for teledermoscopy (modelled in this study as equal to the in-person 
dermatologist reimbursement fee) increases the cost-effectiveness of the teledermoscopy 
service.  
 
To effectively implement teledermoscopy services at the substitution rates that achieve 
desirable cost-effectiveness a streamlined dermoscopic image capture process for general 
practice would be essential7,22. Capturing dermoscopic images and completing a digital 
referral form could increase general practice appointment time by as much as 11:32 minutes 
(range 7:02–26:44)23, this may serve as a disincentive to GPs in the Australian fee-for-service 
model. Using support staff could reduce this barrier to implementation, once the GP has 
identified the lesions of interest, they could capture the images and complete some of the 
digital referral7. 
 
Further research around the clinical significance of expedited clinical resolution and its 
importance for patients could inform implementation recommendations for the Australian 
setting. Similarly, research into what the consumers are willing to pay for teledermoscopy 
given its ability to reduce the time to clinical resolution. If teledermoscopy remains unfunded 
by the government then patients may be willing to self-fund the service in a private capacity 
to reduce their travel and receive a faster specialist opinion.   
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Strengths and Limitations 
The model examined costs and benefits from the perspective of the Australian 
Commonwealth Government in community outpatient settings. The results are therefore only 
applicable to the Australian healthcare setting. This model was not applicable to patients 
treated through alternate clinical pathways, including those who receive inpatient treatment in 
a hospital. Due to limited data regarding teledermoscopy in Australia, the model endpoint 
was classified as clinical resolution; either dermatologist diagnosis or excision with 
histopathology confirmation of diagnosis by either a GP or a dermatologist.  The model does 
not distinguish between GPs who are working in GP clinics and those working in skin cancer 
clinics; referral and excision rates for the later may vary from those presented24.  
 
Although few previous economic models have examined the cost-effectiveness of 
teledermoscopy service provision, there are several randomised controlled trials and 
observational trials that have collected cost information alongside their clinical data14,25.  One 
strength of this study is that actual cost data were used to inform our model for all items 
except the teledermoscopy fee. 
 
Several costs that were excluded in the model, for example, those associated with hospital 
treatments or referrals managed in a hospital, biopsies, and the costs incurred by patients (co-
payments and other out-of-pocket expenses). Patient-incurred costs are likely to be significant 
for patients who need to travel from rural areas to access metropolitan dermatologists in the 
usual care scenario. Australia has travel subsidy and reimbursement schemes for eligible 
patients, however they are only available to patients in the public hospital system, not those 
accessing care through community-based medical practices as described in this model. 
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Therefore, if teledermoscopy as described in this model was examined from a societal 
perspective, it would likely have superior cost-effectiveness to usual care.  
 
Not excising benign lesions that would otherwise be removed may be an optimal outcome for 
teledermoscopy. The change in excision rates for benign neoplasm as a measure of 
effectiveness assumes that optimal clinical resolution would be to leave benign neoplasms 
intact. However, patients often request benign lesions be excised for cosmetic, discomfort or 
other reasons, therefore, the costs for benign lesion excision may have been 
underestimated26,27.  
 
Time in days to clinical resolution was taken from a New Zealand study as the best available 
source. This is relevant to the Australian context because New Zealand also has a very high 
incidence of skin cancers and a similar health system to the Australia28. The use of 
international values may have the potential to under or overestimated the time components in 
this model. However, the New Zealand values used to populate the model fall within the 
range of time in days to clinical resolution shown by other international studies. These other 
studies examining teledermoscopy referral reported 13-50 days when using teledermoscopy 
referral, and 61-138 days for usual care8-10,29.  
 
Conclusion 
Teledermoscopy for skin cancer referral and triage in Australia will increase the cost per 
case, but reduce time to clinical resolution, when compared to usual care. Implementation 
recommendations depend on the preferences of the Australian health system decision makers 
for either lower cost or expedited clinical resolution.  
 
15 
 
  
16 
 
Acknowledgements:  
 
Author Contributions:  
Mrs Centaine Snoswell, had full access to all of the data in the study and take responsibility 
for the integrity of the data and the accuracy of the data analysis. 
Study concept and design: Snoswell, Whitty, Soyer, and Gordon. 
Acquisition, analysis, and interpretation of data: Snoswell, Whitty, and Gordon. 
Drafting of the manuscript: Snoswell, Caffery, and Gordon. 
Critical revision of the manuscript for important intellectual content: Snoswell, Caffery 
Whitty, Soyer, and Gordon. 
Statistical analysis: Snoswell, Whitty, and Gordon. 
Obtained funding: Nil, this study was funded from existing salaries. 
Administrative, technical, or material support: Snoswell, Caffery Whitty, Soyer, and Gordon. 
Study supervision: Snoswell, Whitty, and Gordon. 
 
Funding/Support: 
This study was supported in part by the Centre of Research Excellence in Telehealth funded 
by NHMRC (grant ID: APP1061183). 
Design and conduct of the study: Yes 
Collection, management, analysis and interpretation of data: No 
Preparation, review, or approval of the manuscript: Yes 
Decision to submit the manuscript for publication: No 
 
Role of the Sponsors: The NHMRC grant (grant ID: APP1061183) for the Centre of 
Research Excellence in Telehealth funded part of the non-primary authors’wages (those 
involved in the design, and collection management and approval of the manuscript). The 
primary author was supported by an Australian Government Research Training Program 
(RTP) Scholarship. 
 
Financial Disclosure: 
H. Peter Soyer is a shareholder of e-derm consult GmbH and MoleMap by Dermatologists 
Ltd Pty. He provides teledermatological reports regularly for both companies. 
  
17 
 
4. References  
1. Australian Institute of Health and Welfare. Skin cancer in Australia. Canberra: 
AIHW;2016. Cat. no. CAN 96. 
2. BöRVE A, Dahlén Gyllencreutz J, Terstappen K, et al. Smartphone teledermoscopy 
referrals: a novel process for improved triage of skin cancer patients. Acta dermato-
venereologica. 2015;95(2):186-190. 
3. Congalton A, Oakley A, Rademaker M, Bramley D, Martin R. Successful melanoma 
triage by a virtual lesion clinic (teledermatoscopy). Journal of the European Academy 
of Dermatology and Venereology. 2015. 
4. Moreno-Ramirez D, Ferrandiz L, Nieto-Garcia A, et al. Store-and-forward 
teledermatology in skin cancer triage: experience and evaluation of 2009 
teleconsultations. Archives of Dermatology. 2007;143(4):479-483. 
5. Tan E, Yung A, Jameson M, Oakley A, Rademaker M. Successful triage of patients 
referred to a skin lesion clinic using teledermoscopy (IMAGE IT trial). British 
Journal of Dermatology. 2010;162(4):803-811. 
6. Finnane A, Dallest K, Janda M, Soyer HP. Teledermatology for the Diagnosis and 
Management of Skin Cancer: A Systematic Review. JAMA Dermatol. 
2017;153(3):319-327. 
7. Caffery LJ, Farjian M, Smith AC. Telehealth interventions for reducing waiting lists 
and waiting times for specialist outpatient services: A scoping review. Journal of 
telemedicine and telecare. 2016;22(8):504-512. 
8. Lim D, Oakley AM, Rademaker M. Better, sooner, more convenient: a successful 
teledermoscopy service. Australasian Journal of Dermatology. 2012;53(1):22-25. 
9. Moreno-Ramirez D, Ferrandiz L, Ruiz-de-Casas A, et al. Economic evaluation of a 
store-and-forward teledermatology system for skin cancer patients. J Telemed 
18 
 
Telecare. 2009;15(1):40-45. 
10. Whited JD, Datta S, Hall RP, et al. An economic analysis of a store and forward 
teledermatology consult system. Telemed J E Health. 2003;9(4):351-360. 
11. Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions--a valuable tool for 
early diagnosis of melanoma. Lancet Oncol. 2001;2(7):443-449. 
12. Bashshur RL, Shannon GW, Tejasvi T, Kvedar JC, Gates M. The Empirical 
Foundations of Teledermatology: A Review of the Research Evidence. Telemed J E 
Health. 2015;21(12):953-979. 
13. Rosendahl C. Dermatoscopy in general practice. British Journal of Dermatology. 
2016;175(4):673-674. 
14. Snoswell C, Finnane A, Janda M, Soyer HP, Whitty JA. Cost-effectiveness of Store-
and-Forward Teledermatology: A Systematic Review. JAMA dermatology. 2016. 
15. Medicare Benefits Schedule Book. In: Australian Government Department of Health, 
ed. ISBN: 978-1-76007-226-1: Commonwealth of Australia; 2016. 
16. Britt H, Miller GC, Henderson J, et al. General practice activity in Australia 2013-
2014 - Bettering the Evaluation and Care of Health (BEACH). 2014. 
17. Application No. 1360.1 – Specialist dermatology services delivered by asynchronous 
store and forward technology. In: Medical Services Advisory Committee, ed. 
http://www.health.gov.au/internet/msac/publishing.nsf/Content/21799DF1CF99AC93
CA25801000123C0D/$File/1360.1-FinalPSD-accessible.pdf: Medical Services 
Advisory Committee, ; 2017. 
18. Gordon L, Youl PH, Elwood M, et al. Diagnosis and management costs of suspicious 
skin lesions from a population-based melanoma screening programme. Journal of 
medical screening. 2007;14(2):98-102. 
19. Whited JD, Hall RP, Foy ME, et al. Teledermatology's impact on time to intervention 
19 
 
among referrals to a dermatology consult service. Telemedicine journal and e-health : 
the official journal of the American Telemedicine Association. 2002;8(3):313-321. 
20. Datta SK, Warshaw EM, Edison KE, et al. Cost and Utility Analysis of a Store-and-
Forward Teledermatology Referral System: A Randomized Clinical Trial. JAMA 
dermatology. 2015:1-7. 
21. Pak HS, Datta SK, Triplett CA, Lindquist JH, Grambow SC, Whited JD. Cost 
minimization analysis of a store-and-forward teledermatology consult system. 
Telemed J E Health. 2009;15(2):160-165. 
22. Landow SM, Mateus A, Korgavkar K, Nightingale D, Weinstock MA. 
Teledermatology: key factors associated with reducing face-to-face dermatology 
visits. Journal of the American Academy of Dermatology. 2014;71(3):570-576. 
23. Berghout RM, Eminović N, de Keizer NF, Birnie E. Evaluation of general 
practitioner's time investment during a store-and-forward teledermatology 
consultation. international journal of medical informatics. 2007;76:S384-S391. 
24. Rosendahl C, Williams G, Eley D, et al. The impact of subspecialization and 
dermatoscopy use on accuracy of melanoma diagnosis among primary care doctors in 
Australia. Journal of the American Academy of Dermatology. 2012;67(5):846-852. 
25. Eminović N, Dijkgraaf MG, Berghout RM, Prins AH, Bindels PJ, de Keizer NF. A 
cost minimisation analysis in teledermatology: model-based approach. BMC Health 
Services Research. 2010;10:251-251. 
26. Marks R, Jolley D, McCormack C, Dorevitch A. Who removes pigmented skin 
lesions?: A study of the ratio of melanoma to other benign pigmented tumors removed 
by different categories of physicians in Australia in 1989 and 1994. Journal of the 
American Academy of Dermatology. 1997;36(5):721-726. 
27. Baade PD, Youl PH, Janda M, Whiteman DC, Del Mar CB, Aitken JF. Factors 
20 
 
associated with the number of lesions excised for each skin cancer: a study of primary 
care physicians in Queensland, Australia. Archives of dermatology. 
2008;144(11):1468-1476. 
28. Morton C, Downie F, Auld S, et al. Community photo‐triage for skin cancer referrals: 
an aid to service delivery. Clinical and experimental dermatology. 2011;36(3):248-
254. 
29. Ferrandiz L, Moreno-Ramirez D, Ruiz-de-Casas A, et al. [An economic analysis of 
presurgical teledermatology in patients with nonmelanoma skin cancer]. Actas 
Dermosifiliogr. 2008;99(10):795-802. 
30. English DR, Del Mar C, Burton RC. Factors influencing the number needed to excise: 
excision rates of pigmented lesions by general practitioners. Medical journal of 
Australia. 2004;180(1):16-19. 
31. Taylor R. Sensitivity and Specificity of Malignant Melanoma, Squamous Cell 
Carcinoma, and Basal Cell Carcinoma in a General Dermatological Practice 2012. 
32. Massone C, Maak D, Hofmann‐Wellenhof R, Soyer H, Frühauf J. Teledermatology 
for skin cancer prevention: an experience on 690 Austrian patients. Journal of the 
European Academy of Dermatology and Venereology. 2014;28(8):1103-1108. 
 
  
21 
 
5. Figure Legends 
 
Figure 1. Decision analytic model structure. 
Figure 1 shows the decision analytic model structure, demonstrating the decision nodes and 
end points that were used in the model.  
 
Figure 2. 1-way sensitivity analysis for model inputs expressed in incremental cost-
effectiveness ratio values (cost per days to clinical resolution). 
Figure 2 shows the output for a 1-way sensitivity analysis expressed as an incremental cost-
effectiveness ratio in the form of a tornado diagram.  
 
Figure 3. Probabilistic sensitivity analysis simulation for cost-effectiveness (cost per 
days to clinical resolution). 
Figure 3 shows the scatter-plot output from the probabilistic sensitivity analysis simulation. It 
demonstrates a clear divide between the estimates for usual care and teledermoscopy care.  
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6. Tables 
Table 1. Cost and probability estimates (rows continue on next page) 
Variable Model 
estimate 
(AUD$) 
Sensitivity values  Distribution 
parameters 
Source 
Minimum 
(AUD$) 
Maximum 
(AUD$) 
Costs    Gamma  
GP consultation fee $37.05 $37.05 
(1 consult) 
$111.15 
(3 consults) 
α=6.10, 
ʎ=0.16 
MBS item 2315 
Dermatologist consultation 
fee 
$72.75 $72.75 
(1 consult) 
$145.5 
(2 consults) 
α=23.52, 
ʎ=0.32 
MBS item 10415 
 
Dermatologist 
teledermatology consult 
$72.75 $36.38 
(50%) 
$109.125 
(150%) 
α=23.52, 
ʎ=0.32 
MSAC Application 
(refers to MBS item 
104)15,17  
Cost of histopathology $107.12 $107.12 
(1 instance) 
$214.24 
(2 instances) 
α=28.69, 
ʎ=0.27 
Weighted average of 
MBS items 72816-
18 and 7283015 
Average cost for benign 
neoplasm excision 
$91.72 $76.4 
(lowest 
MBS cost) 
$126.05 
(highest MBS 
cost) 
α=84.13, 
ʎ=0.92 
Weighted average of 
MBS items 31200-
3121015 
Average cost for 
keratinocyte skin cancer 
excision 
$157.36 $155.85 
(lowest 
MBS cost) 
$299.25 
(highest MBS 
cost) 
α=39.62, 
ʎ=0.25 
Weighted average of 
MBS items 31255–
3129015 
Average cost for 
melanoma skin cancer 
excision 
$250.92 $278.65 
(lowest 
MBS cost) 
$369 (highest 
MBS cost) 
α=279.83, 
ʎ=1.12 
Weighted average of 
MBS items 31300–
3133515 
Average cost for any skin 
cancer excision 
(keratinocyte or melanoma 
skin cancer) 
$161.08 $155.85 
(lowest 
MBS cost) 
$369 (highest 
MBS cost) 
α=21.18, 
ʎ=0.13 
Weighted average of 
MBS items 31200-
31210, 31255-
31290, and 31300-
3133515 
Probabilities    Beta  
GP refer to dermatologist 
(usual care)  
0.31 0.19 0.31 α=165.46, 
β=368.29 
BEACH Report 
2013-201416 
GP management condition 
without referral (usual 
care) 
0.7 0.4 0.7 α=9.51, 
β=4.08 
BEACH Report 
2013-20149 
GP refer to dermatologist 
via teledermatology  
0.64 0.15 0.85 α=9.60, 
β=5.40 
Morton 201128 
Post-teledermatology 
patient return to GP for 
management 
0.7 0.4 0.7 α=58.10, 
β=24.90 
Snoswell, 201614 
Post-teledermatology 
patient attend in-person 
appointment with 
dermatologist  
0.2879 0.02 0.8 α=3.20, 
β=7.93 
Moreno-Ramirez 
20074 
GP excise melanoma skin 
cancer 
0.03 0.01 0.09 α=34.89, 
β=1128.11 
English, 200430 
GP excise keratinocyte 
skin cancer  
0.67 0.19 0.96 α=8.10, 
β=3.99 
English, 200430 
Dermatologist in-person 
excise melanoma skin 
cancer 
0.112 0.088 0.173 α=56.72, 
β=449.71 
Taylor 201231 
Dermatologist in-person 
excise keratinocyte skin 
cancer 
0.247 0.1 0.8 α=18.13, 
β=55.27 
Taylor 201231 
Post-teledermatology GP 
consult and no action 
0.2 0.2 0.8 α=12.60, 
β=50.4 
Massone 201432 
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Table 21. Cost and probability estimates (rows continue from previous page) 
Variable Model 
estimate 
(AUD$) 
Sensitivity values  Distribution 
parameters 
Source 
Minimum 
(AUD$) 
Maximum 
(AUD$) 
Post-teledermatology GP 
consult and excise 
melanoma skin cancer 
0.01 0.01 0.09 α=3.95, 
β=391.05 
Massone 201432 
Post-teledermatology GP 
consult and excise 
keratinocyte skin cancer 
0.22 0.2 0.96 α=14.88, 
β=52.76 
Massone 201432 
Outcome      
Time (days) from GP 
consult to GP excision 
without referral. 
1 0 1 No 
distribution 
Same on both arms, 
therefore set to 1.  
Time (days) from GP to 
final resolution (excision 
or dermatologist 
appointment) in usual care 
114 61 138 No 
distribution 
Lim 20128,14 
Time (days) from GP to 
final resolution (excision 
or dermatologist 
appointment) via 
teledermatology 
39 13 50 No 
distribution 
Lim 20128,14 
Time (days) between GP 
teledermatology referral 
and GP no action  
2 1 7 No 
distribution 
Lim 20128,14 
 
Table 32. Incremental cost-effectiveness analysis 
Group Mean Cost ($AUD) Mean time to clinical 
resolution (days) 
Usual care $263.75 35 
Usual care with 
teledermoscopy 
$318.39 9 
Difference $54.64 (95%CrI $22.69 to $97.35) 26 (95%CrI 13 to 38) 
 
Incremental cost-
effectiveness ratio  
 
$2.10 (95%CrI $0.87 to $5.29) per day saved to clinical resolution 
 
 
 
